Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803

Journal of the National Cancer Institute

Volumn 103, Issue 20, 2011, Pages 1540-1551

  Ng, Kimmie ^a   Ogino, Shuji ^a,b   Meyerhardt, Jeffrey A ^a   Chan, Jennifer A ^a   Chan, Andrew T ^b,c   Niedzwiecki, Donna ^d   Hollis, Donna ^d   Saltz, Leonard B ^e   Mayer, Robert J ^a   Benson, Al B ^f   Schaefer, Paul L ^g   Whittom, Renaud ^h   Hantel, Alexander ⁱ   Goldberg, Richard M ^j   Bertagnolli, Monica M ^b   Venook, Alan P ^k   Fuchs, Charles S ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g Toledo Community Hospital Oncology Program   (United States)

^h HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

ⁱ Edward Cancer Center   (United States)

^j UNIVERSITY OF NORTH CAROLINA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FLUOROURACIL; FOLINIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; K RAS PROTEIN;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; COLON CANCER; DIARRHEA; DISEASE FREE SURVIVAL; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RISK ASSESSMENT; RISK FACTORS;

EID: 80052956941     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr307     Document Type: Article

References (51)

1. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-1009. (Pubitemid 26338729)
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
3. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287(24):3215-3222. (Pubitemid 34686102)
4. Casey PJ. Protein lipidation in cell signaling. Science. 1995;268(5208):221-225.
5. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425-430.
6. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184-2192. (Pubitemid 40727085)
7. Samadder NJ, Gupta A, Rennert G et al. In: Statins and the risk of colorectal cancer: a meta-analysis of 22 observational studies. San Antonio, TX: American College of Gastroenterology; 2010. Abstract 1481.
8. Ditah I, Janarthanan S, Kutait A et al. Statin use and the risk of colorectal cancer: has recent evidence shifted our opinion? A meta-analysis involving more than 1.7 million participants. In: San Antonio, TX: American College of Gastroenterology; 2010. Abstract 383.
9. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol. 2006;24(30):4808-4817. (Pubitemid 46655612)
10. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol. 2007;25(23):3462-3468. (Pubitemid 47310884)
11. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456-3461. (Pubitemid 47310883)
12. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005;7(3):413-421. (Pubitemid 41149657)
13. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009;15(23):7322-7329.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
15. Therneau T, Grambsch P. Modeling Survival Data. New York, NY: Springer; 2000.
16. Jones MP, Crowley J. A general class of nonparametric tests for survival analysis. Biometrics. 1989;45(1):157-170. (Pubitemid 19109164)
17. Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text. 2nd ed. New York, NY: Springer Science + Business Media, LLC; 2005.
18. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24(22):3535-3541. (Pubitemid 46630523)
19. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359(9314):1309-1310. (Pubitemid 34310638)
20. Wu Y, Takkenberg JJ, Grunkemeier GL. Measuring follow-up completeness. Ann Thorac Surg. 2008;85(4):1155-1157. (Pubitemid 351381672)
21. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs. 2009;69(11):1445-1457.
22. Singh H, Mahmud SM, Turner D, Xue L, Demers AA, Bernstein CN. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol. 2009;104(12):3015-3023.
23. Yang YX, Hennessy S, Propert K, Hwang WT, Sarkar M, Lewis JD. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf. 2008;17(9):869-876.
24. Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R, Mandelson MT. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3076-3080.
25. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology. 2007;133(2):393-402. (Pubitemid 47187349)
26. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst. 2007;99(1):32-40.
27. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst. 2006;98(1):69-72. (Pubitemid 43057094)
28. Robertson DJ, Riis AH, Friis S, Pedersen L, Baron JA, Sorensen HT. Neither long-term statin use nor atherosclerotic disease is associated with risk of colorectal cancer. Clin Gastroenterol Hepatol. 2010;8(12):1056-1061.
29. Siddiqui AA, Nazario H, Mahgoub A, Patel M, Cipher D, Spechler SJ. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci. 2009;54(6):1307-1311.
30. Lee J, Jung KH, Park YS, et al. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol. 2009;64(4):657-663.
31. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA. 1999;96(14):7797-7802. (Pubitemid 29328361)
32. Ukomadu C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem. 2003;278(44):43586-43594. (Pubitemid 37345984)
33. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999;5(8):2223-2229. (Pubitemid 29399281)
34. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res. 2004;64(18):6461-6468. (Pubitemid 39297901)
35. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105(6):739-745. (Pubitemid 34157379)
36. Alber HF, Dulak J, Frick M, et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol. 2002;39(12):1951-1955. (Pubitemid 34628275)
37. Nubel T, Dippold W, Kleinert H, Kaina B, Fritz G. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J. 2004;18(1):140-142.
38. Broitman SA, Wilkinson J IV, Cerda S, Branch SK. Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo. Adv Exp Med Biol. 1996;401:111-130. (Pubitemid 26326195)
39. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res. 2003;93(10):948-956. (Pubitemid 37441285)
40. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005;5(12):930-942. (Pubitemid 41766782)
41. Rao S, Cunningham D, de Gramont A, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol. 2004;22(19):3950-3957. (Pubitemid 41079877)
42. Sharma S, Kemeny N, Kelsen DP, et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol. 2002;13(7):1067-1071.
43. Macdonald JS, McCoy S, Whitehead RP, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs. 2005;23(5):485-487. (Pubitemid 41160096)
44. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21(9):1760-1766. (Pubitemid 46638589)
45. Thomsen RW, Johnsen SP, Olesen AV, et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol. 2005;60(5):534-542. (Pubitemid 41532454)
46. Neutel CI, Morrison H, Campbell NR, de Groh M. Statin use in Canadians: trends, determinants and persistence. Can J Public Health. 2007;98(5):412-416.
47. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-3995.
48. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer. 2007;96(8):1166-1169. (Pubitemid 46625066)
49. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22):3230-3237. (Pubitemid 47325606)
50. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67(6):2643-2648. (Pubitemid 46548951)
51. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2011;304(16):1812-1820.